Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
X-ray attenuation in tissues refers to the weakening of an x-ray beam as it passes through biological materials, primarily due to absorption and scattering processes[5][3][1][2]. The degree of attenuation is determined by factors such as the tissue’s density, thickness, and atomic number. Denser and higher atomic number tissues (like bone) attenuate x-rays more strongly than less dense tissues (like fat)[2][3][5]. X-ray attenuation is a fundamental principle enabling image contrast in radiography and computed tomography (CT), allowing differentiation between various tissues[1][2]. It is typically quantified by the attenuation coefficient and is not a molecular, cellular, or druggable target, but a macroscopic physical property used in imaging diagnostics[5][2]. \n\nThis term is not a biological target such as a receptor, enzyme, transporter, or gene product, and thus does not have associated pharmacology, biomarkers, or safety concerns[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-ray attenuation in tissues.